文献速递复苏、休克与脓毒症儿科与产科急症

平衡液与生理盐水用于脓毒症的实用儿科试验:PRoMPT BOLUS随机对照试验可行性研究

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: The PRoMPT BOLUS Randomized Controlled Trial Pilot Feasibility Study.
PubMed 文献 · Acad Emerg Med · 2019-07-18
一句话结论在单中心儿科急诊,采用实用随机设计比较乳酸林格液与0.9%生理盐水用于疑似脓毒症休克患儿液体复苏是可行的:59例合格患儿中50例(85%)入组随机化。

该研究为单中心、开放标签、实用随机对照试验,2018年1月至8月在儿童医院急诊科开展,纳入>6个月至<18岁疑似脓毒症休克患儿(定义为血培养、肠外抗生素及因灌注异常行液体复苏)。患儿随机接受乳酸林格液或0.9%生理盐水,最长48小时,其他治疗由临床团队决定。主要可行性终点为入组比例、EFIC知情同意豁免的可接受性及对研究液体的依从性。结果:59例合格患儿中50例(85%)入组;44例经EFIC入组者仅1例(2%)退出;乳酸林格液组研究液体中位生理盐水占比20%(13%–32%),生理盐水组为99%(64%–100%),绝对差79%(95%CI 48%–85%)。结论:实用设计用于比较两种液体复苏效果是可行的。

要点

  • 单中心儿科急诊实用随机试验中,59例合格疑似脓毒症休克患儿有50例(85%)成功入组随机化,证明该设计可行。
  • 经美国联邦EFIC法规入组的44例中仅1例(2%)在完成前退出,提示EFIC入组方式可接受。
  • 乳酸林格液组接受的研究液体中位仅20%(13%–32%)为生理盐水,生理盐水组为99%(64%–100%),绝对差79%(95%CI 48%–85%)。
  • 干预窗口内总晶体液中位数:乳酸林格液组107(60–155)mL/kg vs 生理盐水组98(63–128)mL/kg(p=0.50)。
  • 研究未报告临床疗效终点,结论限于实用随机设计在儿科脓毒症休克液体比较中的可行性。

适用人群与场景

  • >6个月至<18岁、在急诊科因疑似脓毒症休克接受治疗的患儿;疑似脓毒症休克定义为血培养、肠外抗生素及因灌注异常行液体复苏。
  • 单中心学术儿童医院急诊科,2018年1月至8月。

处置流程与药物剂量

  • 符合条件患儿随机接受乳酸林格液或0.9%生理盐水,最长48小时;除液体类型外所有治疗决策由临床团队自行决定。
  • 筛查、入组和随机化由临床团队作为常规诊疗的一部分完成。

研究设计与关键结果

  • 研究类型:单中心、开放标签、实用随机对照试验,2018年1月至8月。
  • 样本量:59例合格患儿中50例(85%)入组随机化,乳酸林格液组24例,生理盐水组26例。
  • 经EFIC入组的44例中仅1例(2%)在完成前退出。
  • 干预窗口内总晶体液量中位数(IQR):乳酸林格液组107(60–155)mL/kg vs 生理盐水组98(63–128)mL/kg(p=0.50)。
  • 乳酸林格液组研究液体中生理盐水占比中位数20%(13%–32%),生理盐水组99%(64%–100%),绝对差79%(95%CI 48%–85%)。

证据类型、等级与局限

  • 证据类型:单中心、开放标签、实用随机对照试验(先导可行性研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,实用研究设计用于比较乳酸林格液与0.9%生理盐水在儿科脓毒症休克液体复苏中的效果是可行的。
  • 研究未报告临床疗效结果,未据此给出液体选择的推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Resuscitation with crystalloid fluid is a cornerstone of pediatric septic shock treatment. However, the optimal type of crystalloid fluid is unknown. We aimed to determine the feasibility of conducting a pragmatic randomized trial to compare balanced (lactated Ringer's [LR]) with 0.9% normal saline (NS) fluid resuscitation in children with suspected septic shock.

METHODS: Open-label pragmatic randomized controlled trial at a single academic children's hospital from January to August 2018. Eligible patients were >6 months to <18 years old who were treated in the emergency department for suspected septic shock, operationalized as blood culture, parenteral antibiotics, and fluid resuscitation for abnormal perfusion. Screening, enrollment, and randomization were carried out by the clinical team as part of routine care. Patients were randomized to receive either LR or NS for up to 48 hours following randomization. Other than fluid type, all treatment decisions were at the clinical team's discretion. Feasibility outcomes included proportion of eligible patients enrolled, acceptability of enrollment via the U.S. federal exception from informed consent (EFIC) regulations, and adherence to randomized study fluid administration.

RESULTS: Of 59 eligible patients, 50 (85%) were enrolled and randomized. Twenty-four were randomized to LR and 26 to NS. Only one (2%) of 44 patients enrolled using EFIC withdrew before study completion. Total median (interquartile range [IQR]) crystalloid fluid volume received during the intervention window was 107 (60 to 155) mL/kg and 98 (63 to 128) mL/kg in the LR and NS arms, respectively (p = 0.50). Patients randomized to LR received a median (IQR) of only 20% (13 to 32) of all study fluid as NS compared to 99% (64% to 100%) of study fluid as NS in the NS arm (absolute difference = 79%, 95% CI = 48% to 85%).

CONCLUSIONS: A pragmatic study design proved feasible to study comparative effectiveness of LR versus NS fluid resuscitation for pediatric septic shock.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Balamuth F, Kittick M, McBride P, et al. Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: The PRoMPT BOLUS Randomized Controlled Trial Pilot Feasibility Study. Acad Emerg Med. 2019. PMID: 31183919. doi:10.1111/acem.13815

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。